ATE526965T1 - Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung - Google Patents

Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung

Info

Publication number: ATE526965T1
Authority: AT; Austria
Prior art keywords: present; disease; delaying; preventing; alzheimer
Prior art date: 2005-04-15

Application number

AT06727482T

Other languages

English (en)

Inventor

Alberta Leon

Carbonare Maurizio Dalle

Original Assignee

Res & Innovation S P A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-15

Filing date

2006-04-14

Publication date

2011-10-15

2005-04-15 Priority claimed from ITPD20050109 external-priority patent/ITPD20050109A1/it

2006-01-19 Priority claimed from ITPD20060014 external-priority patent/ITPD20060014A1/it

2006-04-14 Application filed by Res & Innovation S P A filed Critical Res & Innovation S P A

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526965T1 publication Critical patent/ATE526965T1/de

Links

208000037259 Amyloid Plaque Diseases 0.000 title abstract 2
230000002159 abnormal effect Effects 0.000 title abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 2
SVJMLYUFVDMUHP-XIFFEERXSA-N (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-XIFFEERXSA-N 0.000 abstract 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 abstract 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 abstract 1
208000024777 Prion disease Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
230000003942 amyloidogenic effect Effects 0.000 abstract 1
206010002022 amyloidosis Diseases 0.000 abstract 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
239000002260 anti-inflammatory agent Substances 0.000 abstract 1
239000003963 antioxidant agent Substances 0.000 abstract 1
230000003078 antioxidant effect Effects 0.000 abstract 1
235000006708 antioxidants Nutrition 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 abstract 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003580 felodipine Drugs 0.000 abstract 1
ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 abstract 1
229960003963 manidipine Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960001783 nicardipine Drugs 0.000 abstract 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
229960001597 nifedipine Drugs 0.000 abstract 1
229950010800 niguldipine Drugs 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
208000008864 scrapie Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT06727482T 2005-04-15 2006-04-14 Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung ATE526965T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ITPD20050109 ITPD20050109A1 (it)	2005-04-15	2005-04-15	Metodo per prevenire, ritardare o revertire la progressione di patologie associate ad un anormale accumulo di proteina amiloide.
ITPD20060014 ITPD20060014A1 (it)	2006-01-19	2006-01-19	Metodo per alimentare l'efflusso dal sistema nervoso di peptidi amiloidei
PCT/IB2006/000886 WO2006109164A2 (en)	2005-04-15	2006-04-14	A method for preventing, delaying or reverting abnormal amyloid deposition

Publications (1)

Publication Number	Publication Date
ATE526965T1 true ATE526965T1 (de)	2011-10-15

Family

ID=36972727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06727482T ATE526965T1 (de)	2005-04-15	2006-04-14	Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung

Country Status (5)

Country	Link
EP (1)	EP1874311B1 (de)
AT (1)	ATE526965T1 (de)
ES (1)	ES2374716T3 (de)
PT (1)	PT1874311E (de)
WO (1)	WO2006109164A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2761298A1 (en) *	2009-05-15	2010-11-18	The University Of Kentucky Research Foundation	Treatment of mci and alzheimer's disease
US9968574B2 (en)	2009-05-15	2018-05-15	The University Of Kentucky Research Foundation	Treatment of MCI and Alzheimer's disease
JP2013526518A (ja) *	2010-05-13	2013-06-24	ザユニバーシティオブケンタッキーリサーチファウンデーション	Ｍｃｉおよびアルツハイマー病の処置
CN107937476A (zh) *	2017-12-22	2018-04-20	临沂齐泽医药技术有限公司	一种治疗高血压(s)‑马尼地平的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998049144A1 (en) *	1997-04-25	1998-11-05	Ajinomoto Co., Inc.	Novel dihydropyridine derivative
ES2289814T3 (es) *	1998-07-10	2008-02-01	Novartis Pharma Ag	Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.
EP1123923A4 (de) *	1998-10-23	2002-11-27	Ajinomoto Kk	Dihydropyridin-derivate und drogen gemenge, die diese enthalten
WO2000078719A1 (en) *	1999-06-23	2000-12-28	Ajinomoto Co., Inc.	Dihydropyridine derivative
WO2002078670A1 (en) *	2001-03-02	2002-10-10	Neuron Therapeutics, Inc.	Neuroprotectants formulations and methods
TW200306799A (en) *	2002-05-17	2003-12-01	Novartis Ag	Combination of organic compounds
WO2004110354A2 (en) *	2003-05-15	2004-12-23	Roskamp Research, Llc	Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
ES2309594T3 (es) *	2003-11-21	2008-12-16	Memory Pharmaceuticals Corporation	Composiciones que contienen bloqueadores de los canales de calcio de tipo l e inhibidores de la colinesterasa.

2006
- 2006-04-14 ES ES06727482T patent/ES2374716T3/es not_active Expired - Lifetime
- 2006-04-14 AT AT06727482T patent/ATE526965T1/de active
- 2006-04-14 PT PT06727482T patent/PT1874311E/pt unknown
- 2006-04-14 WO PCT/IB2006/000886 patent/WO2006109164A2/en not_active Ceased
- 2006-04-14 EP EP06727482A patent/EP1874311B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2374716T3 (es)	2012-02-21
PT1874311E (pt)	2011-11-25
WO2006109164A2 (en)	2006-10-19
EP1874311B1 (de)	2011-10-05
EP1874311A2 (de)	2008-01-09
WO2006109164A3 (en)	2007-03-29

Similar Documents

Publication	Publication Date	Title
EA201000714A1 (ru)	2010-10-29	Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета амилоидного пептида
EA200971050A1 (ru)	2010-06-30	Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
WO2006001877A3 (en)	2006-02-16	Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
Llorens et al.	2017	Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease
CL2008001960A1 (es)	2009-11-27	Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
EA201190020A1 (ru)	2012-02-28	Производные изоиндола в качестве ингибиторов васе и их применение
AU2019268069A1 (en)	2019-12-12	Methods and compositions for improving cognitive function
EA200601494A1 (ru)	2007-02-27	Имидазольные соединения для лечения нейродегенеративных расстройств
ME02728B (de)	2017-10-20	Verbindungen und ihre verwendung als bace-inhibitoren
WO2004071431A3 (en)	2004-12-02	Method and composition for treating neurodegenerative disorders
ATE540681T1 (de)	2012-01-15	Verfahren zur behandlung von atherosklerose
NO20050122L (no)	2005-01-10	Prodrug av eksitasjonsaminosyrer
WO2008104385A8 (en)	2009-10-08	Method for the treatment of amyloidoses
WO2008066626A3 (en)	2008-12-11	METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
Guo et al.	2020	Reparative effects of stem cell factor and granulocyte colony-stimulating factor in aged APP/PS1 mice
WO2007129221A8 (en)	2008-04-10	Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
WO2006109164A3 (en)	2007-03-29	A method for preventing, delaying or reverting abnormal amyloid deposition
MX2022007654A (es)	2022-07-19	Compuestos inhibidores de la oga.
NO20064989L (no)	2007-01-02	Sulfonamidforbindelser for behandling av neurodegenerative lidelser
WO2005016267A3 (en)	2005-04-21	Oxazole compounds for the treatment of neurodegenerative disorders
WO2007056580A3 (en)	2007-08-16	Methods and compositions for treating diseases associated with pathogenic proteins
WO2008018639A3 (en)	2008-04-03	Glycine transporter inhibitor
GT200900206A (es)	2011-08-18	Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica
EP1797035A4 (de)	2009-08-05	Cyclopropylpiperidinglycin-transporter-inhibitor
ATE402150T1 (de)	2008-08-15	Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen

Legal Events

Date

Code

Title

Description

2012-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1874311

Country of ref document: EP